Initial studies suggest that the compound – a dual stimulator of incretin and GIP receptors – may provide a considerable breakthrough in metabolic reduction programs . In contrast to existing medications , the peptide seems to influence appetite and metabolic expenditure by means of multiple pathways . Despite additional copyrightination is re